ZBTB7B

Across TCGA pan-cancer cohorts, ZBTB7B mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ZBTB7B data layer compared with 23 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ZBTB7B mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ZBTB7B expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

PDAC, GBM, and CCRCC are the cancer types where ZBTB7B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	III,IV	0.261	0.772	.002	10	view →
GBM	DFS	Tertile	All	0.268	0.531	.007	6	view →
CCRCC	DFS	Median	All	0.990	0.849	.011	5	view →
LUAD	OS	Tertile	II,III,IV	1.000	0.887	.041	1	view →
LSCC	OS	Tertile	All	0.875	0.930	.038	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ZBTB7B–PDAC (OS)

Open the PDAC breakdown →